List of Excipients in Branded Drug FLECAINIDE ACETATE

« Back to Dashboard

Generic Drugs Containing FLECAINIDE ACETATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	flecainide acetate	0054-0010	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	flecainide acetate	0054-0010	CROSCARMELLOSE SODIUM
Hikma Pharmaceuticals USA Inc	flecainide acetate	0054-0010	HYDROGENATED COTTONSEED OIL
Hikma Pharmaceuticals USA Inc	flecainide acetate	0054-0010	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	flecainide acetate	0054-0010	STARCH, CORN
Epic Pharma LLC	flecainide acetate	42806-817	CELLULOSE, MICROCRYSTALLINE
Epic Pharma LLC	flecainide acetate	42806-817	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in FLECAINIDE ACETATE?

# Of NDCs	Excipient
38	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE
1	COTTONSEED OIL
39	CROSCARMELLOSE SODIUM
9	HYDROGENATED COTTONSEED OIL
2	HYDROGENATED OLIVE OIL
39	MAGNESIUM STEARATE

Flecainide Acetate Excipient Strategy and Commercial Opportunities

Last updated: October 25, 2026

Flecainide acetate is an established Class IC antiarrhythmic available primarily as immediate-release oral tablets and injectable solution. Its commercial opportunity is not based on basic generic substitution alone. The strongest opportunities are in low-cost, bioequivalent tablet platforms; ready-to-use oral liquids; pediatric and dysphagia-friendly dosage forms; hospital injection products; and differentiated formulations that improve dose flexibility without changing flecainide exposure.

Flecainide has a narrow therapeutic range, substantial interpatient variability, and clinically important renal and hepatic clearance considerations. Excipient selection must therefore protect dose uniformity, dissolution, stability, and bioequivalence. Formulation changes that alter gastrointestinal release or absorption can create regulatory and clinical risk.

What excipients are used in flecainide acetate tablets?

Flecainide acetate tablets commonly use lactose or another diluent, pregelatinized starch or microcrystalline cellulose as a filler and binder, croscarmellose sodium or sodium starch glycolate as a disintegrant, colloidal silicon dioxide as a glidant, and magnesium stearate as a lubricant.

Exact excipient composition varies by manufacturer and strength. FDA labeling identifies inactive ingredients for individual products, but those compositions should not be treated as universal for all flecainide acetate tablets.[1]

Formulation function	Common excipient candidates	Commercial relevance
Dilution and tablet mass	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Supports low-dose 50 mg tablets and manufacturing robustness
Binding	Pregelatinized starch, povidone, hydroxypropyl cellulose	Controls tablet hardness and friability
Disintegration	Croscarmellose sodium, sodium starch glycolate, crospovidone	Supports rapid immediate-release dissolution
Flow improvement	Colloidal silicon dioxide	Important for direct compression and content uniformity
Lubrication	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and tooling wear
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Enables strength identification, moisture protection, and swallowability
Taste management	Sucralose, saccharin sodium, fruit flavors, ion-exchange resin systems	Relevant to oral liquids and chewable or dispersible products

The main development constraint is not the number of available excipients. It is maintaining rapid, reproducible dissolution while controlling assay uniformity across 50 mg, 100 mg, and 150 mg strengths.

How does flecainide acetate’s chemistry affect excipient selection?

Flecainide acetate is a basic, relatively lipophilic antiarrhythmic compound. The acetate salt supports oral formulation, but pH, ionic strength, and microenvironmental solubility can influence dissolution and precipitation behavior. Public drug databases report a molecular weight of approximately 474.9 g/mol for flecainide acetate, while the flecainide free base has a molecular weight of approximately 414.9 g/mol.[2]

Formulators should evaluate four material attributes:

1. Salt form and pH sensitivity. Acidic or alkaline excipients can change local solubility and dissolution.
2. Particle size. The active pharmaceutical ingredient’s particle-size distribution can affect blend uniformity and release.
3. Moisture sensitivity. Hygroscopic excipients and high-moisture processing can affect flow, compression, and stability.
4. Lubricant exposure. Excess magnesium stearate can reduce wetting and slow dissolution.

A direct-compression formulation using microcrystalline cellulose, a superdisintegrant, colloidal silicon dioxide, and controlled magnesium stearate is a commercially practical starting point. Wet granulation may improve content uniformity and flow but introduces additional process variables and drying requirements.

What formulations are protected by flecainide acetate patents?

Flecainide acetate’s original branded product, Tambocor, lost primary small-molecule exclusivity many years ago. Current US commercial products are predominantly generic immediate-release tablets marketed under ANDAs. The core composition and use claims associated with the original product are unlikely to provide meaningful blocking protection for a new generic manufacturer.

The relevant IP opportunity is more likely to arise from later formulation or delivery claims, including:

• Stable oral suspensions or ready-to-use liquids.
• Taste-masked liquid formulations.
• Unit-dose sachets or oral dosing systems.
• Modified-release tablets.
• Pediatric dispersible tablets.
• Multiparticulate or sprinkle formulations.
• Manufacturing processes that improve content uniformity.
• Packaging systems that improve moisture or light stability.
• Combination products involving flecainide and another antiarrhythmic or rate-control agent.

Patentability would depend on claim scope, technical effect, comparative data, and the prior-art record. A simple substitution of one conventional filler for another would generally present a weak inventive-step position.

When does flecainide acetate lose exclusivity?

Flecainide acetate has already lost regulatory exclusivity in the United States and major international markets. FDA-approved generic tablets are available, and the product is not dependent on current new chemical entity exclusivity.

Milestone	Commercial position
Original branded product	Tambocor
Current US pathway	ANDA generic tablets and other approved dosage forms
NCE exclusivity	Expired
Core small-molecule patent position	Historical protection expired
Current competition	Generic manufacturers and established suppliers
Main remaining barriers	Bioequivalence, manufacturing economics, supply reliability, formulation differentiation

The absence of active core exclusivity does not eliminate formulation IP. A new dosage form can still obtain patent protection if it produces a non-obvious technical result and is claimed separately from the expired immediate-release tablet.

What is the FDA regulatory status of flecainide acetate?

Flecainide acetate is FDA-approved for specified rhythm-control indications, including documented sustained ventricular tachycardia and selected supraventricular arrhythmias under labeled conditions. The FDA label carries important warnings concerning proarrhythmic effects and use in patients with structural heart disease or prior myocardial infarction.[1]

The principal regulatory routes are:

• ANDA: Standard route for a tablet that references an approved immediate-release product.
• 505(b)(2): Potential route for a new oral liquid, modified-release product, or other dosage form that relies partly on FDA findings for an approved product.
• NDA: Relevant for a genuinely novel formulation, combination, or delivery system.
• Compounded preparation: Not a conventional commercial approval route and generally less attractive for broad market access.

A new tablet formulation may qualify for a biowaiver only if it satisfies applicable regulatory requirements. Given flecainide’s narrow therapeutic index, applicants should expect close attention to dissolution, pharmacokinetic variability, dose proportionality, and product sameness.

What is the Orange Book status of flecainide acetate?

FDA Orange Book status should be reviewed product by product because listed patents, exclusivity, and reference-product designations attach to specific approved applications.[3] The central commercial point is that flecainide acetate is a mature generic market rather than a protected branded market.

For an ANDA applicant, the principal diligence items are:

Orange Book issue	Flecainide relevance
Reference listed drug	Identify the current reference product for the proposed strength and dosage form
Listed patents	Confirm whether any patent remains listed against the selected reference application
Exclusivity	Confirm absence or expiration of relevant market exclusivity
Paragraph IV risk	Relevant only if an unexpired listed patent remains
Paragraph III or IV certification	Selected according to the patent status shown for the reference product
Suitability petition	Potentially relevant for a dosage-form or strength difference, subject to FDA requirements

A Paragraph IV strategy is most relevant to a newly approved formulation with listed patents, not to the long-established conventional flecainide tablet market. A formulation developer should not assume that an expired core product creates freedom to commercialize every liquid, modified-release, or pediatric presentation.

Which companies are challenging flecainide acetate patents?

The conventional flecainide acetate market is characterized by generic competition rather than a current, high-profile patent challenge involving the original product. Generic manufacturers can enter through ANDA filings once applicable exclusivity and patent barriers have expired.

Publicly relevant competitive groups include:

• Established generic manufacturers with oral solid-dose capacity.
• Contract development and manufacturing organizations offering low-volume specialty products.
• Hospital injectable suppliers.
• Regional pharmaceutical companies serving markets where antiarrhythmic products remain physician-directed.
• Specialty manufacturers developing pediatric or dysphagia-oriented dosage forms.

A complete current list of pending Paragraph IV challengers requires a live review of FDA litigation records, the Orange Book, and federal court dockets. Patent litigation is not the primary commercial barrier for the established immediate-release tablet.

What excipient strategy is best for an immediate-release tablet?

The most defensible platform is a robust, low-cost immediate-release formulation with limited excipient complexity.

Recommended development architecture

A practical formulation screen would compare:

• Microcrystalline cellulose versus lactose-based filler systems.
• Croscarmellose sodium versus crospovidone.
• Direct compression versus dry granulation.
• Magnesium stearate versus sodium stearyl fumarate.
• Standard film coating versus moisture-protective coating.

The target profile should include:

• Rapid dissolution across physiologically relevant pH conditions.
• Low tablet-to-tablet weight variation.
• Reliable assay and content uniformity at the 50 mg strength.
• Adequate hardness without delayed disintegration.
• Stable performance after accelerated storage.
• Consistent release across all marketed strengths.

The 50 mg tablet may present the greatest content-uniformity challenge because the active represents a smaller fraction of total tablet mass. Geometric dilution, ordered mixing, or granulation may be preferable to a simple low-shear blend.

Excipient risks

Lactose can create formulation issues for patients with intolerance, although the amount in a tablet is often small. Magnesium stearate can slow dissolution when overused or excessively blended. High levels of hygroscopic disintegrants can affect stability. Titanium dioxide and colorants can complicate supply qualification, regional registration, and customer preferences.

A lactose-free formulation can create commercial differentiation, particularly for hospital formularies, specialty pharmacies, and patients who prefer simplified excipient profiles.

What commercial opportunities exist for flecainide oral liquids?

A ready-to-use oral liquid is the clearest formulation opportunity. Flecainide is used in patients who may have difficulty swallowing tablets, including children with inherited arrhythmia syndromes, older adults, and patients receiving enteral nutrition.

A commercial oral liquid would need to address:

• Chemical stability over the proposed shelf life.
• Uniform concentration throughout the bottle.
• Accurate dosing at low volumes.
• Taste masking.
• Compatibility with oral syringes and feeding tubes.
• Protection against microbial growth.
• Low sedimentation or rapid redispersion if the product is a suspension.
• Packaging that prevents dosing errors.

A solution is operationally simpler if adequate solubility and taste can be achieved. A suspension may offer greater formulation flexibility but requires validated redispersion, dose uniformity, particle-size control, and patient-use instructions.

Taste masking is a central commercial issue. Conventional sweeteners alone may not sufficiently suppress the bitter or medicinal taste of flecainide. Potential approaches include polymeric coating, ion-exchange resins, cyclodextrin systems, or pH-controlled flavor optimization. These approaches can support formulation patents if they deliver measurable improvement in palatability without compromising absorption.

Are modified-release and pediatric formulations commercially attractive?

Modified-release flecainide could reduce dosing frequency, but it carries higher development risk. Flecainide dosing is individualized, and controlled release could complicate titration, renal impairment management, and treatment of adverse effects. A modified-release product would require strong pharmacokinetic justification and may not fit the prescribing habits established around immediate-release tablets.

Pediatric dispersible tablets, mini-tablets, or sprinkle capsules have a more focused opportunity. These products could provide flexible dosing while avoiding the stability and microbial-control burden of a liquid. Commercial value would depend on pediatric labeling, dose flexibility, palatability, and access to specialist cardiology channels.

Product concept	Patient need	Development risk	IP potential
Generic immediate-release tablet	Low-cost substitution	Low to moderate	Low
Lactose-free tablet	Excipient preference and formulary differentiation	Low	Low
Ready-to-use oral solution	Dysphagia and pediatric dosing	Moderate	Moderate
Oral suspension	Flexible dosing and taste masking	Moderate to high	Moderate
Dispersible mini-tablet	Pediatric and swallowing support	Moderate	Moderate
Modified-release tablet	Reduced dosing frequency	High	High if technically differentiated
Unit-dose liquid	Medication safety and adherence	Moderate	Moderate

What manufacturing and IP barriers affect commercialization?

Manufacturing barriers are manageable for standard tablets but more significant for liquids and specialty dosage forms.

The key operational requirements are:

• Qualified API supply with consistent salt form and particle-size profile.
• Blend uniformity at the 50 mg strength.
• Validated dissolution methods capable of detecting formulation drift.
• Stability-indicating analytical methods.
• Low-dose liquid filling accuracy.
• Container-closure compatibility.
• Control of microbial contamination in aqueous products.
• Supply continuity for flavors, resins, coating polymers, and specialty packaging.

The strongest IP position would likely come from a formulation package combining composition, manufacturing process, packaging, and a defined pharmacokinetic or palatability advantage. A single broad claim covering "flecainide in a liquid formulation" would face substantial validity risk because oral liquids and suspensions are conventional dosage forms.

How strong is the flecainide acetate patent estate?

The core patent estate is weak from a blocking perspective because the product is an old, established small molecule with broad generic availability. The commercial patent opportunity is concentrated in secondary patents.

IP category	Relative strength
Original composition-of-matter protection	Expired
Conventional immediate-release tablet	Weak
Standard excipient substitution	Weak
Taste-masked oral liquid	Moderate, if supported by comparative data
Pediatric dispersible dosage form	Moderate
Modified-release system	Potentially strong, but technically demanding
Packaging and stability claims	Moderate
Manufacturing process claims	Moderate if process-specific and non-obvious
Combination therapy claims	Fact-specific and potentially constrained by prior art

Patent value will depend less on the active ingredient and more on whether the formulation solves a documented clinical or manufacturing problem.

What generic launch scenarios exist?

Low-cost tablet launch

This is the fastest and lowest-risk route. Competition will focus on API cost, manufacturing scale, supply reliability, wholesaler access, and formulary contracting. Margins are likely to be constrained.

Specialty oral-liquid launch

A liquid can support higher pricing if it addresses pediatric and dysphagia needs that conventional tablets do not serve. The product may compete in a smaller market with less direct price pressure.

Hospital injection launch

Flecainide acetate injection, where approved and commercially supplied, can support hospital and emergency-care procurement. Sterile manufacturing, container compatibility, and supply continuity are the main barriers. The injectable market is more sensitive to shortages and contract reliability than to consumer branding.

Differentiated pediatric launch

A dispersible, mini-tablet, or unit-dose product could support specialist distribution and potentially stronger lifecycle protection. Regulatory development would be more complex than for a standard ANDA tablet.

How does flecainide acetate compare with competing antiarrhythmics?

Flecainide competes clinically with other rhythm-control agents, including propafenone, sotalol, amiodarone, and selected alternatives used under specialist supervision. The comparison is driven by indication, structural heart disease, renal function, proarrhythmic risk, monitoring burden, and dosage form.

Drug	Commercial formulation opportunity	Main differentiation issue
Flecainide acetate	Pediatric liquid, dispersible tablet, reliable generic tablet	Narrow therapeutic range and cardiac safety profile
Propafenone	Immediate- and extended-release products	Broader formulation competition
Sotalol	Tablets and oral solution opportunities	Renal dosing and QT monitoring
Amiodarone	Tablets, injection, and complex excipient profiles	Long half-life and organ toxicity
Dronedarone	Branded differentiated product	Higher commercial and regulatory barriers

Flecainide’s opportunity is strongest where formulation convenience matters and where prescribers need a familiar active ingredient with flexible dosing.

What revenue exposure exists for manufacturers and investors?

Public sources do not provide a consistently reliable molecule-level revenue figure for all flecainide acetate products. Commercial exposure is likely fragmented across generic tablets, hospital injectables, and regional specialty products rather than concentrated in one dominant branded franchise.

Revenue drivers include:

• Number of approved strengths.
• Generic price erosion.
• Hospital-contract wins.
• Pediatric and liquid-product differentiation.
• Supply shortages affecting competitors.
• API cost and manufacturing yield.
• Geographic registration footprint.
• Ability to secure reimbursement for a premium dosage form.

The standard tablet is primarily a volume business. The liquid, pediatric, and hospital segments offer better pricing potential but require more regulatory and manufacturing investment.

What geographic markets offer the best opportunity?

The United States offers a mature generic market with clear FDA pathways but strong price competition. Europe offers fragmented national reimbursement and registration requirements, with opportunities for pediatric and hospital products. Emerging markets may provide stronger demand for affordable tablets but impose local registration, pricing, and distribution constraints.

A regional strategy should prioritize:

1. The United States for high-quality generic entry and specialty 505(b)(2) opportunities.
2. Major European markets for pediatric and hospital formulations.
3. Markets with limited access to oral liquids or injectable antiarrhythmics.
4. Countries where local manufacturing or supply reliability is valued in procurement.

Key Takeaways

• Flecainide acetate is a mature generic active ingredient with expired core exclusivity.
• Conventional immediate-release tablets offer the lowest development risk but the weakest pricing power.
• The most credible commercial opportunities are ready-to-use oral liquids, pediatric dispersible products, lactose-free tablets, and hospital injection supply.
• Excipient selection must prioritize rapid dissolution, content uniformity, stability, and predictable exposure.
• Taste masking, liquid stability, packaging, and pediatric dosing can support secondary patent positions.
• Modified-release products may offer stronger IP but face higher pharmacokinetic and regulatory risk.
• Paragraph IV litigation is not the central issue for the established tablet market; formulation-specific patents would create the more relevant challenge.
• Manufacturing reliability, API quality, low-dose uniformity, and sterile capacity are more important commercial barriers than the expired core patent estate.

FAQs About Flecainide Acetate Excipient and Formulation Opportunities

Can flecainide acetate be formulated without lactose?

Yes. Microcrystalline cellulose, dibasic calcium phosphate, mannitol, or other compatible diluents can replace lactose, subject to dissolution, stability, compression, and bioequivalence testing.

Is a flecainide acetate oral suspension commercially viable?

Yes. An oral suspension can address pediatric and swallowing-related needs, but it requires validated sedimentation control, redispersion, dose uniformity, microbial preservation, palatability, and packaging performance.

Can a new flecainide formulation qualify for 505(b)(2) approval?

Potentially. A new oral liquid, modified-release dosage form, or other differentiated product may use the 505(b)(2) pathway if it relies partly on FDA findings for an approved flecainide product and satisfies applicable clinical and pharmaceutical requirements.

What is the most valuable secondary patent strategy for flecainide?

A formulation patent supported by comparative data is more valuable than a conventional excipient substitution claim. Stronger candidates include stable taste-masked liquids, pediatric dosage systems, modified-release platforms, and packaging that solves a demonstrated stability problem.

Does flecainide acetate have a biosimilar risk?

No. Flecainide acetate is a chemically synthesized small molecule, not a biologic. Competitive entry occurs through generic-drug pathways such as ANDA approval rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (n.d.). Flecainide acetate prescribing information. FDA labeling database and DailyMed product labeling.

2. National Center for Biotechnology Information. (n.d.). PubChem compound summary: Flecainide acetate. PubChem.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. U.S. Food and Drug Administration. (2015). Abbreviated new drug application submissions: Refuse-to-receive standards guidance for industry. FDA.

5. U.S. Food and Drug Administration. (1995). Immediate release solid oral dosage forms: Scale-up and post-approval changes guidance for industry. FDA.

6. European Medicines Agency. (n.d.). Flecainide-containing medicinal products: Product information and regulatory materials. EMA.